![Banner Video](https://cdn.georgeinstitute.org/sites/default/files/styles/width1920_fallback/public/2019-09/banner-videos_1.jpg)
The TRACK Trial
Improving cardiovascular health of patients with chronic kidney disease. The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning medication, would reduce cardiovascular death or major cardiovascular events in patients with advanced stages of chronic kidney disease.